Tests a shorter radiation course after surgery for womb and cervical cancer
Tests shorter radiation after surgery in adults with womb or cervical cancer.
Plain-language title generated from the registry record
Registry title: Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study
Key facts
- Where
- Mumbai and Navi Mumbai, IndiaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05857631, who can take part
Where in India
- Tata Memorial HospitalMumbai, IndiaTaking people
- Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)Navi Mumbai, IndiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tata Memorial Centre
- Trial code
- NCT05857631
- Record updated
- 15 April 2025
- Original description
The primary aim of the trial is to investigate the late effects of hypofractionated external radiation (39 Gy in 13 fractions) in patients requiring post-operative radiation for early-stage cervical and endometrial cancers.Read full original descriptionShow less
Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study
The primary aim of the trial is to investigate the late effects of hypofractionated external radiation (39 Gy in 13 fractions) in patients requiring post-operative radiation for early-stage cervical and endometrial cancers.
Inclusion: Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; Histologically confirmed diagnosis of cervical cancer post hysterectomy with intermediate or high-risk features, requiring adjuvant EBRT ± concurrent chemotherapy OR histologically confirmed diagnosis of endometrial cancer post hysterectomy requiring adjuvant (chemo)radiotherapy to pelvis with/without vaginal brachytherapy.
Exclusion: Patients treated with pelvic radiation previously; Patients with macroscopic residual disease (R+ resection) postoperatively; Patients requiring extended field radiotherapy (patients with involved para-aortic lymph nodes in cervical or endometrial cancer); Patients treated with chemotherapy for any prior malignancy at any time; Patients with human immunodeficiency virus infection; Any preexisting medical conditions that may interfere with the assessment of genitourinary or gastrointestinal toxicity (This includes patients with irritable bowel syndrome, subacute intestinal obstruction, anal incontinence, hemorrhoids precluding analysis of gastro-intestinal toxicities, urinary incontinence, recurrent urinary tract infections).